Articles Archives - KIFFIK Biomedical Inc. | Revolutionizing diagnostics through the power of ISF

Articles

Tapping into the body’s ISF ‘superhighway’ for early disease detection

By extracting and analyzing biomarker data in interstitial fluid (ISF), we can better detect and treat a range of diseases much earlier. June 3, 2025 Medical Design & Outsourcing Pending FDA approval, the Kiffik Lab will be commercially available for at-home colorectal cancer testing in mid-2026. [Image courtesy of Kiffik Biomedical] In the mid-1800s, British physician Dr. Henry Bence Jones began testing the blood and urine of patients to look for signs of a protein indicative of multiple myeloma. Bence Jones is credited as being the first to explore biomarker …

Articles

KIFFIK Biomedical partners with Duracell & Rubix

Powering the Future of Diagnostics PHTA’s first resident, KIFFIK Biomedical, is changing the diagnostics landscape with a needle-free, interstitial fluid (ISF)-based diagnostic platform, the KIFFIK Lab™ – offering fast, accurate, and at-home disease detection. Now, through strategic partnerships with Duracell and Rubix, KIFFIK is accelerating the next generation of biomarker-driven diagnostics. These collaborations, supported by the PHTA ecosystem, are not just advancing cancer screening but also opening doors for broader industry innovation. “At KIFFIK, we believe that the future of diagnostics lies in harnessing the rich biomarker profile of interstitial …

Tapping into the body’s ISF ‘superhighway’ for early disease detection

KIFFIK Biomedical partners with Duracell & Rubix

Navigation

FOLLOW US

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Estradiol (E2)

Luteinizing Hormone (LH)

Progesterone

Follicle-Stimulating Hormone (FSH)

Anti-Müllerian Hormone (AMH)

Hormonal health shouldn’t be a guessing game. With KIFFIK, women can see their cycle, and their care, more clearly than ever before.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Interleukin-6 (IL-6)

S100B (neurotrauma indicator)

Lactate (tissue hypoxia)

D-dimer (coagulation dysfunction)

Myoglobin (muscle damage)

TNF-α (systemic inflammation)

When every second counts, insight can’t wait for the hospital. KIFFIK’s platform is designed to move with the mission — delivering data where it’s needed most.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Prostate-Specific Antigen (PSA)

PCA3 (Prostate Cancer Antigen 3)

Alpha-methylacyl-CoA racemase (AMACR)

Circulating tumor DNA (ctDNA) for mutation profiling

Interleukin-8 (IL-8) and other inflammation markers

Continuous insight without constant disruption, KIFFIK’s platform enables smarter, patient-centered care for prostate cancer across the spectrum of disease.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

IL-6, CRP (inflammatory signaling)

Adiponectin, leptin (metabolic regulation)

VEGF, IL-8 (oncogenic pathways)

S100B, GFAP (neuroinflammatory injury)

Every breakthrough begins with better data. KIFFIK gives researchers a new lens on human biology, continuously, painlessly, and in real time.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Procalcitonin (PCT)

C-reactive protein (CRP)

Interleukin-6 (IL-6)

TNF-α (Tumor Necrosis Factor-alpha)

Lactate

When sepsis moves fast, we have to move faster. KIFFIK’s platform could help detect the warning signs before symptoms spiral.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Interleukin-1α (IL-1α)

Interleukin-8 (IL-8)

TNF-α

MMP-9 (Matrix metalloproteinase-9)

Reactive oxygen species (ROS)

Natural moisturizing factor (NMF) markers

The skin is always speaking — through irritation, inflammation, and subtle shifts. With ISF, we can finally hear it clearly, and respond in real time.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

GFAP (Glial Fibrillary Acidic Protein)

UCH-L1 (Ubiquitin C-terminal hydrolase L1)

S100B

Interleukin-6 (IL-6)

Tau protein fragments

Early detection of brain injury doesn't have to wait for imaging. With ISF, it could happen in minutes — where it matters most.

The challenge.

The opportunity.

Clinical application:

Potential biomoarkers:

Carcinoembryonic antigen (CEA)